+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
KIMIABL KIMIABL

Kimia Biosciences Share Price

₹31.40 -0.28 (-0.88%)
42.91% Fall from 52W High

04 Aug, 2026 12:44 PM (IST)

Kimia Biosciences live price: ₹31.40. It opened at ₹32 vs previous close ₹32; intraday high/low: ₹33/₹31. The 50 & 200 DMA stand at ₹32.70/₹34.60.

Kimia Biosciences Performance

  • Today's Low
  • ₹31
  • Today's High
  • ₹33
  • 52 Week Low
  • ₹23
  • 52 Week High
  • ₹55
  • Open Price₹32
  • Previous Close₹32
  • Volume1,090
  • 50 DMA₹32.70
  • 100 DMA₹33.10
  • 200 DMA₹34.60

Kimia Biosciences Chart

Investment Returns

  • Over 1 Month -2.7%
  • Over 3 Month -10.82%
  • Over 6 Month -1.88%
  • Over 1 Year -43.47%

Smart Investing Starts Here Start SIP with Kimia Biosciences for Steady Growth!

Invest Now

Kimia Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 20
  • PEG Ratio
  • -0.9
  • Market Cap Cr
  • 149
  • P/B Ratio
  • 8.4
  • Average True Range
  • 1.5
  • EPS
  • 1.6
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.3
  • RSI
  • 45.6
  • MFI
  • 71.76

Latest Stock News Updates

Kimia Biosciences Ltd - 530313 - Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015 -Intimation Of Meeting Of Board Of Directors.

Kimia Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Un-Audited Financial Results (Standalone) for the first quarter ended on June 30th, 2026.

Kimia Biosciences Ltd - 530313 - Announcement under Regulation 30 (LODR)-Change in Management

Change in Management, appointment of Cost Auditor, Internal Auditor, Secretarial Auditor and Discountinuance/ Cessation of Secretarial Auditor

Kimia Biosciences Ltd - 530313 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 1, 2026 Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Outcome of the Meeting of the Board of Directors held on August 1, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Appointment of Cost Auditor, Internal Auditor and Secretarial Auditor and Discontinuance of Secretarial Auditor

Kimia Biosciences Financials

Kimia Biosciences Technicals

EMA & SMA

Current Price
₹31.40
-0.28 (-0.88%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹32.10
  • 50 Day
  • ₹32.70
  • 100 Day
  • ₹33.10
  • 200 Day
  • ₹34.60

Resistance and Support

31.67 Pivot Speed
  • R3 32.70
  • R2 32.50
  • R1 32.10
  • S1 31.40
  • S2 31.20
  • S3 30.80

Kimia Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-10 Quarterly Results
2026-05-29 Audited Results
2026-02-14 Quarterly Results
2025-11-14 Quarterly Results
2025-09-04 Final Dividend & A.G.M.

Kimia Biosciences Shareholding Pattern

74.94%
24.68%
0.38%
0%

About Kimia Biosciences

Kimia Biosciences main objective of the Company is to carry on business of Pharamaceutical products. View More
  • NSE Symbol
  • KIMIABL
  • BSE Symbol
  • 530313
  • Chairman.,Executive Director,Managing Director,Chief Executive Officer
  • Sameer Goel
  • ISIN
  • INE285U01025

Similar Stocks to Kimia Biosciences

Kimia Biosciences FAQs

Kimia Biosciences share price is ₹31 As on 04 August, 2026 | 12:33

The Market Cap of Kimia Biosciences is ₹148.6 Cr As on 04 August, 2026 | 12:33

The P/E ratio of Kimia Biosciences is 20 As on 04 August, 2026 | 12:33

The PB ratio of Kimia Biosciences is 8.4 As on 04 August, 2026 | 12:33

The 52 week High & Low of Kimia Biosciences is ₹55/₹23.2 respectively As on 04 August, 2026 | 12:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23